NO954342L - Erytropoietinanalogblandinger, samt fremgangsmåter ved fremstilling derav - Google Patents

Erytropoietinanalogblandinger, samt fremgangsmåter ved fremstilling derav

Info

Publication number
NO954342L
NO954342L NO954342A NO954342A NO954342L NO 954342 L NO954342 L NO 954342L NO 954342 A NO954342 A NO 954342A NO 954342 A NO954342 A NO 954342A NO 954342 L NO954342 L NO 954342L
Authority
NO
Norway
Prior art keywords
well
processes
preparation
erythropoietin analog
analog mixtures
Prior art date
Application number
NO954342A
Other languages
English (en)
Norwegian (no)
Other versions
NO954342D0 (no
Inventor
Gregory F Okasinski
Peter J Devries
Barry S Mellovitz
Joseph L Meuth
Verlyn G Schaefer
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of NO954342D0 publication Critical patent/NO954342D0/no
Publication of NO954342L publication Critical patent/NO954342L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO954342A 1993-04-29 1995-10-30 Erytropoietinanalogblandinger, samt fremgangsmåter ved fremstilling derav NO954342L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5507693A 1993-04-29 1993-04-29
PCT/US1994/004755 WO1994025055A1 (en) 1993-04-29 1994-04-29 Erythropoietin analog compositions and methods

Publications (2)

Publication Number Publication Date
NO954342D0 NO954342D0 (no) 1995-10-30
NO954342L true NO954342L (no) 1995-10-30

Family

ID=21995426

Family Applications (1)

Application Number Title Priority Date Filing Date
NO954342A NO954342L (no) 1993-04-29 1995-10-30 Erytropoietinanalogblandinger, samt fremgangsmåter ved fremstilling derav

Country Status (13)

Country Link
US (1) US5888772A (ja)
EP (1) EP0744953A4 (ja)
JP (1) JPH08509614A (ja)
KR (1) KR960701650A (ja)
CN (1) CN1125401A (ja)
AU (1) AU697453B2 (ja)
BR (1) BR9406490A (ja)
CA (1) CA2161651A1 (ja)
CZ (1) CZ286046B6 (ja)
FI (1) FI955128A (ja)
HU (1) HUT73876A (ja)
NO (1) NO954342L (ja)
WO (1) WO1994025055A1 (ja)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614184A (en) 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
US6153407A (en) * 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
KR100400637B1 (ko) * 1996-02-06 2004-03-10 씨제이 주식회사 생물학적으로유용한펩타이드
US5835382A (en) 1996-04-26 1998-11-10 The Scripps Research Institute Small molecule mimetics of erythropoietin
AU3908597A (en) * 1996-08-02 1998-02-25 Ortho-Mcneil Pharmaceutical, Inc. Polypeptides having a single covalently bound n-terminal water-soluble polymer
US6967092B1 (en) 1996-10-25 2005-11-22 Mc Kearn John P Multi-functional chimeric hematopoietic receptor agonists
US5952226A (en) * 1996-11-05 1999-09-14 Modex Therapeutiques Hypoxia responsive EPO producing cells
CA2693296C (en) 1997-12-08 2013-09-10 Merck Patent Gmbh Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
BR9909583A (pt) * 1998-04-15 2002-01-15 Lexigen Pharm Corp Aumento da resposta imune mediado por uma proteìna de fusão anticorpo-citocina por co-administração com inibidor de angiogênese
AU775422B2 (en) 1998-06-15 2004-07-29 Gtc Biotherapeutics, Inc. Erythropoietin analog-human serum albumin fusion
CA2352538A1 (en) * 1998-11-30 2000-06-08 Eli Lilly And Company Erythropoietic compounds
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
US7309687B1 (en) 1999-04-13 2007-12-18 The Kenneth S. Warren Institute, Inc. Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin
US7345019B1 (en) * 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
ATE316982T1 (de) * 1999-08-09 2006-02-15 Lexigen Pharm Corp Mehrere zytokin-antikörper komplexen
WO2001036489A2 (en) * 1999-11-12 2001-05-25 Merck Patent Gmbh Erythropoietin forms with improved properties
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
ATE336514T1 (de) 2000-02-11 2006-09-15 Merck Patent Gmbh Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
EP1294401B1 (en) * 2000-06-29 2007-08-01 EMD Lexigen Research Center Corp. Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
US7118737B2 (en) 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
JP2004508338A (ja) * 2000-09-08 2004-03-18 グリフォン　セラピューティクス，インコーポレーテッド ポリマー修飾合成タンパク質
WO2002024899A2 (en) 2000-09-25 2002-03-28 Valentis, Inc. Improved system for regulation of transgene expression
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7767643B2 (en) * 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US6531121B2 (en) 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
AU2002248571B2 (en) * 2001-03-07 2007-01-18 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
JP4309662B2 (ja) * 2001-05-03 2009-08-05 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 腫瘍特異的組換え抗体およびその使用
EP2354791A1 (en) * 2001-12-04 2011-08-10 Merck Patent GmbH Immunocytokines with modulated selectivity
EP1552298A4 (en) * 2002-07-01 2006-11-08 Kenneth S Warren Inst Inc RECOMBINANT TISSUE-PROOFING CYTOKINS AND NUCLEIC ACIDS COORDINATING THEREOF FOR THE PROTECTION, RECOVERY AND IMPROVEMENT OF CELLS, TISSUE AND ORGANS THEREOF
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
WO2004055056A1 (en) * 2002-12-17 2004-07-01 Merck Patent Gmbh Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
CA2521273A1 (en) * 2003-04-02 2004-10-21 Epimmune Inc. Peptides, polypeptides, and proteins of reduced immunogenicity and methods for their production
MXPA05010773A (es) 2003-04-09 2005-12-12 Neose Technologies Inc Metodos de glicopegilacion y proteinas/peptidos producidos por los metodos.
US7459152B2 (en) * 2003-04-23 2008-12-02 Rush University Medical Center Erythropoietin administration to improve graft survival
CA2539440A1 (en) * 2003-09-29 2005-04-14 Warren Pharmaceuticals, Inc. Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
EP1699821B1 (en) * 2003-12-31 2012-06-20 Merck Patent GmbH Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
DE102004063927A1 (de) 2004-01-23 2005-12-15 Epoplus Gmbh Co.Kg Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
US7588745B2 (en) * 2004-04-13 2009-09-15 Si Options, Llc Silicon-containing products
KR20090016596A (ko) 2006-05-19 2009-02-16 글리코파이, 인크. 에리트로포이에틴 조성물
JP2010510794A (ja) 2006-11-28 2010-04-08 ハナル ファーマシューティカル カンパニー リミテッド 修飾型エリスロポエチンポリペプチド及びこの治療用用途
CN103113464B (zh) * 2007-07-02 2014-08-20 沈阳三生制药有限责任公司 天然人促红细胞生成素类似物
US20100298219A1 (en) * 2008-01-22 2010-11-25 Anthony Cerami Method of treating cancer, neoplastic disorders, and symptoms thereof with compounds
CN101939443B (zh) 2008-02-08 2014-01-29 Ambrx公司 经修饰瘦素多肽和其用途
EP2342223B1 (en) 2008-09-26 2017-04-26 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
US20100272816A1 (en) 2009-04-27 2010-10-28 Wolfgang Rudinger Microcapsules comprising liver cells and erythropoietin, methods for preparing said microcapsules and methods for treating a patient comprising applying said microcapsules to the patient
US20130034875A1 (en) * 2009-10-01 2013-02-07 Toto Ltd. Dna construct, and process for production of recombinant cho cell using same
CN102205114B (zh) * 2011-04-29 2012-12-12 中国人民解放军第三军医大学 促红细胞生成素来源肽在制备治疗神经系统自身免疫性疾病的药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4835260A (en) * 1987-03-20 1989-05-30 Genetics Institute, Inc. Erythropoietin composition
DE3923963A1 (de) * 1989-07-20 1991-01-31 Behringwerke Ag Muteine des menschlichen erythropoetins, ihre herstellung und ihre verwendung

Also Published As

Publication number Publication date
NO954342D0 (no) 1995-10-30
HU9503088D0 (en) 1995-12-28
EP0744953A1 (en) 1996-12-04
FI955128A0 (fi) 1995-10-27
CN1125401A (zh) 1996-06-26
AU697453B2 (en) 1998-10-08
KR960701650A (ko) 1996-03-28
EP0744953A4 (en) 1998-05-06
BR9406490A (pt) 1996-03-05
US5888772A (en) 1999-03-30
FI955128A (fi) 1995-10-27
CA2161651A1 (en) 1994-11-10
CZ284495A3 (en) 1996-02-14
CZ286046B6 (cs) 1999-12-15
JPH08509614A (ja) 1996-10-15
HUT73876A (en) 1996-10-28
WO1994025055A1 (en) 1994-11-10
AU6778594A (en) 1994-11-21

Similar Documents

Publication Publication Date Title
NO954342L (no) Erytropoietinanalogblandinger, samt fremgangsmåter ved fremstilling derav
EE200000318A (et) Uudsed ühendid
AU6477390A (en) Gas generating compositions containing nitrotriazalone
MX9704030A (es) 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.
HU9601555D0 (en) Process for the preparation of microcapsule compositions
ZA965294B (en) Substituted 4-phenylaminothiazoles, their process of preparation and the pharmaceutical compositions containing them.
ZA965752B (en) Triphenylethylenes, process for their production, pharmaceutical preparations that contain these triphenylethylenes as well as their use for the production of pharmaceutical agents.
IL117091A0 (en) Methylphenyloxazolidinone derivatives pharmaceutical compositions containing the same and processes for the preparation thereof
DK0386452T3 (da) Diphenylheteroalkylderivater, fremgangsmåde til fremstilling heraf og lægemidler og kosmetika indeholdende disse
IL72928A (en) Bronchodilating pharmaceutical compositions containing 5,6-dialkoxybenzothiophene-2-carboxylic acid
HUT41960A (en) Insecticide compositions containing 2,6,7-trioxa-bicyclo/2,2,2/octane derivatives as active agents and process for producing the active agents and intermediates
FR2714063B1 (fr) Procédé de préparation de collagène à partir de cnidaires, et compositions obtenues utilisables en cosmétique.
FI961378A0 (fi) Menetelmä N-metyyli-3-(1-metyyli-4-piperidinyyli)-14-indoli-5-etaanisulfonamidin valmistamiseksi
HUP9601680A3 (en) Benzisothiazolyl-substituted aminomethyl-chromanes, pharmaceutical compositions containing the same, process for their preparation and use of the compounds
IS4081A (is) Aðferð við framleiðslu efnasamsetninga
AU7812794A (en) Pharmaceutical compositions containing n-acetylcarnosine for the treatment of cataract
NO307403B1 (no) Fremgangsmåte for tørr fremstilling av partikler, tørrfremstilte partikler oppnådd på denne måte, samt farmasøytiske blandinger som inneholder slike partikler
AU673401B2 (en) 6,7-dialkoxy-3,4-dihydroisoquinolin-8-ol, process for preparation thereof and process for preparation of 6,7-dialkoxy-1,2,3,4-tetrahydroisoquinolin-8-ol using the compound
IL108632A0 (en) Fluorinated 4-aminoandrostadienone derivatives, their preparation and pharmaceutical compositions containing them
NO903347L (no) 14,17alfa-ethano- og ethanooestratriener, fremgangsmaate forfremstilling av disse forbindelser, saavel som anvendelse av dem for fremstilling av legemidler.
EP0226842A3 (en) Substituted 1,4-naphthalenediones, processes for their preparation and pharmaceutical compositions containing them
HUT52763A (en) Herbicide and growth-controlling compositions containing sulfonyl-urea derivatives as active components and process for producing the active components
HRP960076B1 (en) Substituted benzenesulfonylureas and -thioureas, process for their preparation and the use of pharmaceutical preparations based on these compounds, as well as medicaments containing them
HUP9602324A3 (en) Piperidinyl-methyl-oxazolidinon derivatives, pharmaceutical compositions containing the same, process for the preparation of the compounds and use of them
IL106289A (en) Phospholipid derivatives their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application